Pharmacologist
U.S. Food and Drug Administration
Silver Spring, Maryland
Dr. Xiaofei Wang is currently a clinical pharmacology reviewer in the Division of Clinical Evaluation and Pharmacology/Toxicology, Office of Tissues and Advanced Therapies (OTAT), CBER, FDA. She performs clinical pharmacology reviews for BLA and IND submissions of biological products including cell and gene therapies, blood- and plasma-derived products. Prior to joining CBER, Dr. Wang was a bioequivalence reviewer in Office of Bioequivalence (OB), Office of Generic Drugs (OGD), CDER, FDA. In addition to conducting regulatory reviews, Dr. Wang has also actively participated in multiple FDA working groups developing regulatory guidances. Dr. Wang received her PhD degree in Pharmaceutical Sciences from University of Florida.
Disclosure information not submitted.
Wednesday, October 19, 2022
8:30 AM – 9:00 AM ET